OBJECTIVES: To understand how clinicians in six European countries manage patients with statin intolerance (SI). METHODS: Clinicians from Austria, Belgium, Czech Republic, Denmark, Portugal, and Switzerland were recruited for a web-based survey between 2015 and 2016. Participants were asked how they manage patients with confirmed SI. Both specialists (cardiologists) and general/family physicians (GPs) (60 per country) participated and were required to have treated ≥5 patients presenting with symptoms of SI in the previous year. All participants provided informed consent. RESULTS: Clinicians estimated that, on average, 50% (range across countries [RAC] 43–61%) of their high-risk patients with confirmed SI continue to receive statins at a dose below the recommended therapeutic dose. On average, 69% (RAC 60–83%) of high-risk patients with confirmed SI receive a non-statin lipid-lowering therapy (LLT) alone or in combination with a low-dose statin; a small proportion (11%) do not receive any LLT (RAC 5–15%). Specialists and GPs use non-statin LLTs with similar frequency. In all countries except the Czech Republic, the majority of clinicians (85% of specialists and 73% of GPs) reported that ezetimibe was their first choice of non-statin LLT; in the Czech Republic, fenofibrate was preferred by GPs (selected as first choice by 84%) and ezetimibe by specialists (selected as first choice by 80%). Across commonly used non-statin LLTs in all countries, 13–67% of clinicians’ patients were considered to reach lipid goals, and 19–63% of patients were satisfactorily treated in the opinion of the clinician. CONCLUSIONS: Non-statin LLT was commonly prescribed with concomitant low-dose statin in all countries; ezetimibe was the most commonly used non-statin monotherapy in most countries.